FDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial For BL-M14D1 For Neuroendocrine Cancers
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxLow-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxSummary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- Newsletter 37/2025 September 14, 2025
- OST-504: A Novel Immunotherapy Targeting Prostate Cancer September 13, 2025
- Memantine Shows Promise Against Advanced Prostate Cancer September 11, 2025
- Pasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial September 11, 2025